Aeon biopharma announces topline results from phase 2 trial of abp-450 (prabotulinumtoxina) for the preventive treatment of episodic migraine

– abp-450 doses of 150 units and 195 units showed treatment effect of 4.8 days and 5.0 days, respectively, in the mean change from baseline in monthly migraine days (mmd) at weeks 21-24 but did not meet statistical significance vs. placebo because of a much higher-than-expected placebo response of 4.2 days –
AEON Ratings Summary
AEON Quant Ranking